Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: a randomized controlled trial

JAMA : the Journal of the American Medical Association
Michael A Blazing'A to Z' Investigators

Abstract

Enoxaparin or the combination of glycoprotein IIb/IIIa inhibitor tirofiban with unfractionated heparin independently have shown superior efficacy over unfractionated heparin alone in patients with non-ST-elevation acute coronary syndromes (ACS). It is not clear if combining enoxaparin with glycoprotein IIb/IIIa inhibitors is as safe or as effective as the current standard combination of unfractionated heparin with glycoprotein IIb/IIIa inhibitors. To assess efficacy and safety of the combination of enoxaparin and tirofiban compared with unfractionated heparin and tirofiban in patients with non-ST-elevation ACS. A prospective, international, open-label, randomized, noninferiority trial of 1 mg/kg of enoxaparin every 12 hours (n = 2026) compared with weight-adjusted intravenous unfractionated heparin (n = 1961) in patients with non-ST-elevation ACS receiving tirofiban and aspirin. Phase A of the A to Z trial was conducted between December 1999 and May 2002. Death, recurrent myocardial infarction, or refractory ischemia at 7 days in the intent-to-treat population with boundaries set for superiority and noninferiority. Safety based on measures of bleeding using the Thrombolysis in Myocardial Infarction (TIMI) classification system....Continue Reading

Citations

May 1, 2007·Future Cardiology·Eric R Bates
Jun 22, 2007·Vascular Health and Risk Management·Caroline Schmidt-Lucke, Heinz-Peter Schultheiss
May 17, 2007·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Vijay S Ramanath, Kim A Eagle
Nov 29, 2007·Vojnosanitetski pregled. Military-medical and pharmaceutical review·Nebojsa DespotovićSinisa Dimković
Jul 30, 2005·Journal of Thrombosis and Thrombolysis·Pranab Das, David J Moliterno
Dec 23, 2008·Journal of Thrombosis and Thrombolysis·Tobias HeerUNKNOWN Acute Coronary Syndromes (ACOS) Registry Investigators
Jul 10, 2008·Current Cardiology Reports·Peter E Ruchin, Marino Labinaz
May 7, 2010·Current Cardiology Reports·Amit P Amin, Steven P Marso
Jul 3, 2009·Journal of Cardiovascular Medicine·Raffaele De Caterina
Sep 13, 2011·International Journal of Clinical Pharmacy·A A ZeitounM M Zeineddine
Mar 14, 2012·PharmacoEconomics·Jaime Latour-Pérez, Eva de-Miguel-Balsa
Oct 20, 2005·Current Opinion in Cardiology·Sameer K Mehta, James A de Lemos
May 11, 2007·Expert Review of Cardiovascular Therapy·Sinjin Lee, C Michael Gibson
Dec 14, 2007·Expert Opinion on Pharmacotherapy·Edith A Nutescu, Karen Steinmetz Pater
Oct 29, 2009·Expert Opinion on Drug Safety·Nicolas Meneveau
Jan 19, 2016·Journal of Thrombosis and Thrombolysis·Maureen A SmytheAnn K Wittkowsky
Mar 8, 2016·European Heart Journal·Uwe ZeymerGilles Montalescot
May 3, 2013·Thrombosis and Haemostasis·R De CaterinaUNKNOWN European Society of Cardiology Working Group on Thrombosis Task Force on Anticoagulants in Heart Disease
Aug 17, 2005·Journal of Thrombosis and Haemostasis : JTH·D R PhillipsP Andre
Sep 10, 2005·Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions·Glenn N LevineKeith A A Fox
Jul 11, 2007·Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions·A DanaG R Barbeau
Jun 30, 2007·Journal of Internal Medicine·E V Gelfand, C P Cannon
Dec 2, 2004·Expert Opinion on Pharmacotherapy·Terje R Pedersen, Jonathan A Tobert
Dec 2, 2005·Expert Opinion on Pharmacotherapy·David B Brieger
Apr 8, 2011·Expert Opinion on Pharmacotherapy·Zafar Iqbal, Marc Cohen
Jun 17, 2005·Expert Opinion on Pharmacotherapy·John M Galla, Kenneth W Mahaffey
Nov 27, 2007·Journal of the American College of Cardiology·James A de LemosEugene Braunwald
Apr 6, 2005·Journal of the American College of Cardiology·William W O'NeillCindy L Grines

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.